Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

ClinicalTrials.gov ID: NCT03932201

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03932201. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Observational Study Evaluating Effectiveness and Safety of Real-World Treatment With Damoctocog Alfa Pegol in Previously Treated Patients With Hemophilia A

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is used to treat people with Hemophilia A in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians are with the treatment.

Study identification

NCT ID: NCT03932201
Recruitment status: Active, not recruiting
Study type: Observational
Phase: Not listed
Lead sponsor: Bayer; Industry
Enrollment: 371 participants

Conditions and interventions

Conditions

Hemophilia A

Interventions

Damoctocog alfa pegol (Jivi, Bay94-9027) Drug

Drug

Eligibility (public fields only)

Age range: Not listed
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 21, 2019 (Actual)
Primary completion: Dec 31, 2026 (Estimated)
Completion: Mar 31, 2027 (Estimated)
Last update posted: Jul 1, 2026

2019 – 2027

United States locations

U.S. sites: 10
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
South Alabama Medical Science Foundation	Mobile	Alabama	36688	—
Banner MD Anderson Cancer Center	Phoenix	Arizona	85012	—
University California Davis	Davis	California	95616	—
Orthopaedic Hospital DBA Orthopaedic Institute for Children	Los Angeles	California	90007	—
The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders	Orange	California	92868	—
University of Colorado Hemophilia and Thrombosis Center	Aurora	Colorado	80045	—
Georgetown University	Washington D.C.	District of Columbia	20007	—
Tulane University	New Orleans	Louisiana	70112	—
Regents of University of Minnesota	Minneapolis	Minnesota	55454	—
East Carolina University - Brody School of Medicine	Greenville	North Carolina	27834	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03932201, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 1, 2026 · Synced Nov 15, 2026